In light of recent market events in the Icelandic financial sector, which are a consequence of the world financial crisis, Actavis Group would like to clarify its position.

The financial crisis does not impact our normal course of business, and Actavis will remain focused on providing quality products to its customers.

Actavis Group hf. is not exposed to the Icelandic banks in regards to funding or normal banking facilities. Our banking operations are with international banks not exposed to the current events in Iceland. We therefore, as before, have full banking operations without restrictions, both to make payments and receive payments.

Actavis is a global generic pharmaceutical company with a turnover of about EUR1.7bn this year, with only 1% of our revenues generated in Iceland.

Actavis provides high-quality, low-cost products to its customers in the US, Europe, and other major markets of the world. Notwithstanding the challenges facing the world economy, we continue to experience rising demand and to launch new products.

The company is present in 40 countries around the globe, and its products are registered in more than 60 countries. The company‘s books are in euros.